Financial Performance - Total revenue reached $138 million, a significant increase of 467% year-over-year[5] - US product sales, net, amounted to $25 million, representing a 46% increase year-over-year[5] Prescription Growth - Retail prescription equivalents experienced a 43% year-over-year growth[5] and 6% quarter-over-quarter growth[8] - New to Brand Rx Trends increased by 79%[29] Label Expansion and Market Access - FDA approval of new labels for NEXLETOL and NEXLIZET expands the addressable patient population to over 70 million in the US[8, 13, 19] - The new labels include indications for primary prevention and removal of the statin use qualifier[8, 11] - Utilization management criteria updates by two major payers now cover 40 million lives[9] International Expansion - Medicines Approved in 30+ Countries[33] - International growth continues with 255,000 patients through February '24[37] Financial Position - Q1 2024 cash and cash equivalents totaled $227 million[39] - FY 2024 R&D guidance is $45 - 55 million[40] - FY 2024 SG&A guidance is $180 - 190 million[40] - FY 2024 OpEx guidance is $225 - 245 million, including $20 million of non-cash stock-based compensation expense[40, 41]

Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to loss of $0.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 525%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.53 per share when it actually produced a loss of $0.50, delivering a surprise of 5.66%.Over the last four ...

– Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Expansions Expected Throughout 2024 – – Received U.S. FDA Approval of Broad New Label Expansions for NEXLETOL (bempedoic acid) Tablet and NEXLIZET (bempedoic acid and ezetimibe) Tablet, Becoming the First LDL-C Lowering Non- Statins to Prevent Heart Attacks and Reduce Cardiovascular Risk in Primary and Secondary Prevention Patients – ® ® Exhibit 99.1 Esperion Reports First Quarter 2024 Financial Results – Q1 Total Re ...

ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website. JMP Securities’ Life Sciences Conference in New York on May 13, 2024, at 2:30 p.m. ET. Bank of America Securities’ 2024 Health Care Conference in Las Vegas on May 15, 2024, at 3:00 p.m. PT / 6:00 p.m. ET. H.C. Wainwright’s 2nd Annual BioConnect Investor Conf ...

– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo – – NEXLETOL Demonstrated Clinical Benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients With and Without Cardiovascular Disease (CVD) – – CLEAR Outcomes Sets New Standards for Diversity and Inclusion with Enrollment of 48% Women and 17% Hispanic/Latinx Patients – ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR ...

– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – – Approvals Based on Positive CLEAR Outcomes Data and Reflect a Highly Differentiated Product Profile – – Positive CHMP Opinion Received; European Cardiovascular (CV) Risk Reduction Label Determination Anticipated in Q2 2024 – – Conference Call and Webcast on Monday, March 25 at 8:00 a.m. ET – ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (N ...

– Positive CHMP Opinions Are Based On The Analyses Of The Phase 3 Of The CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)-Inhibiting Regimen) Outcomes Trial1 – – European Commission Decision On Label Update Authorization Applications Are Expected To Be Made In 1H 2024 – ANN ARBOR, Mich. and MUNICH, Germany, March 22, 2024 (GLOBE NEWSWIRE) -- Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo') and Esperion Therapeutics, Inc. jointly announced today, that the Committee for Medic ...

skynesher/E+ via Getty Images After Esperion Therapeutics (NASDAQ:ESPR) rolled out a secondary offering in mid-January, the initial selling looked set to undermine an otherwise promising biotech story. Fortunately, ESPR never looked back from its gap down open and in turn the stock set up a fresh buying opportunity. Roll the calendar forward to the company’s recent earnings report, and I can release my next sigh of relief. The post-earnings gain of 10.3% was not enough for a breakout, but momentum at le ...

Esperion Therapeutics, Inc. (ESPR) incurred a loss per share of 50 cents in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 53 cents. The company incurred a loss of 76 cents per share in the year-ago quarter.Esperion generated revenues of $32.3 million, up 72% year over year. The reported figure beat the Zacks Consensus Estimate of $26.8 million.Quarter in DetailEsperion has two FDA-approved drugs in its commercial portfolio — Nexletol and Nexlizet — that are approved for ...

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.66%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.42 per share when it actually produced a loss of $0.37, delivering a surprise of 11.90%.Over the last four quarters, t ...